Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
Key claim: Oral semaglutide is linked to lower risk of cognitive impairment than DPP-4 inhibitors in elderly patients with HFpEF and obesity.
Abstract
No abstract available.
Why this matters
The GLP-1-as-geroprotector narrative keeps expanding into new organ systems, and cognition is one of its highest-value frontiers for the longevity-clinic pitch. An observational active-comparator signal against DPP-4 inhibitors is a meaningful trend data point but not a substitute for a dedicated cognitive-outcome RCT, and the HFpEF-plus-obesity population is narrow enough that generalization to broader use is where trend momentum will outrun the evidence.